Company Profile

Lisata Therapeutics Inc (AKA: Caladrius Biosciences Inc~Corniche Group Inc~NeoStem Inc)
Profile last edited on: 12/2/2023      CAGE: 4LJL0      UEI: USWTE8MPR7H1

Business Identifier: Cellular therapies for oncology, immunology, and regenerative medicine sectors
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

110 Allen Road 2nd Floor
Basking Ridge, NJ 07920
   (908) 842-0100
Location: Multiple
Congr. District: 07
County: Somerset

Public Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  David J Mazzo -- President and Chief Executive Officer

  Robin L Smith -- Chairman & CEO

  Timothy C Fong -- Vice President - Technology & Product Development, Progenitor Cell Therapy

  George S Goldberger -- Vice President Business Development, Progenitor Cell Therapy

  Hans Keirstead

  Daryl LeSueur -- Vice President Manufacturing Operations, Progenitor Cell Therapy

  Jeffrey Liter -- Chief Operating Officer, Progenitor Cell Therapy

  Douglas W Losordo

  Larry A May -- Chief Financial Officer

  Andrew L Pecora -- Chief Medical Officer and Director

  Stephen W Potter -- Executive Vice President

  Robert A Preti -- President, Progenitor Cell Therapy

  Denis O Rodgerson

  Jonathan Sackner-Bernstein -- Vice President, Clinical Development and Regulatory Affairs

  Martin E Schmieg -- Vice President, Corporate Development

  Joseph Talamo -- Vice President, Corporate Controller and Chief Accounting Officer

  Catherine M Vaczy -- Vice President and General Counsel

  Mark Westgate -- Vice President - Finance, Progenitor Cell Therapy